Fidelity Investments
PLX icon

Fidelity Investments’s Protalix BioTherapeutics PLX Stock Holding History

Fidelity Investments’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.3K Buy
2,905
+590
+25% +$1.46K ﹤0.01% 4868
2025
Q4 		$4.17K Buy
2,315
+1,877
+429% +$3.84K ﹤0.01% 4922
2025
Q3 		$972 Buy
+438
New +$713 ﹤0.01% 5021
2024
Q3 		– Sell
-6,791
Closed -$7.95K – 5681
2024
Q2 		$7.95K Buy
6,791
+4,265
+169% +$5.04K ﹤0.01% 4412
2024
Q1 		$3.18K Buy
2,526
+2,456
+3,509% +$3.67K ﹤0.01% 4611
2023
Q4 		$125 Sell
70
-279
-80% -$434 ﹤0.01% 4923
2023
Q3 		$580 Buy
349
+244
+232% +$438 ﹤0.01% 4700
2023
Q2 		$210 Buy
+105
New +$250 ﹤0.01% 4899
2020
Q3 		– Sell
-2
Closed – – 3924
2020
Q2 		$0 Hold
2
– – ﹤0.01% 4040
2020
Q1 		$0 Hold
2
– – ﹤0.01% 4121
2019
Q4 		$0 Buy
+2
New +$5 ﹤0.01% 4160
2014
Q3 		– Sell
-106,679
Closed -$3.89M – 2815
2014
Q2 		$3.89M Sell
106,679
-8,000
-7% -$323K ﹤0.01% 2293
2014
Q1 		$5.25M Hold
114,679
– – ﹤0.01% 2195
2013
Q4 		$4.46M Hold
114,679
– – ﹤0.01% 2202
2013
Q3 		$5.2M Sell
114,679
-5,230
-4% -$268K ﹤0.01% 2143
2013
Q2 		$5.89M Buy
+119,909
New +$6.36M ﹤0.01% 2091

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Fidelity Investments's PLX Position: Q1 2026 in Review

Fidelity Investments increased its Protalix BioTherapeutics (PLX) stake by 25% in Q1 2026, buying an estimated $1.46K and bringing the position to 2,905 shares worth $6.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4868.

Fidelity Investments first reported a position in PLX in Q2 2013 and has held it in 16 quarters since. The position peaked at $5.89M in Q2 2013. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Fidelity Investments held 2,905 shares of Protalix BioTherapeutics worth $6.3K as of Q1 2026.
  • Fidelity Investments bought 590 Protalix BioTherapeutics shares in Q1 2026, an estimated $1.46K.
  • Protalix BioTherapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4868 holding.
  • Fidelity Investments first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 16 quarters since.
  • Fidelity Investments's Protalix BioTherapeutics position peaked at $5.89M in Q2 2013.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.